Equities research analysts expect that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will report earnings per share of $0.56 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Ionis Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at $1.05. Ionis Pharmaceuticals reported earnings of ($0.01) per share in the same quarter last year, which suggests a positive year over year growth rate of 5,700%. The business is scheduled to announce its next quarterly earnings report on Friday, May 3rd.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.06) per share for the current financial year, with EPS estimates ranging from ($0.74) to $0.80. For the next financial year, analysts expect that the company will post earnings of $0.89 per share, with EPS estimates ranging from ($0.79) to $4.50. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Ionis Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Wednesday, February 27th. The company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $2.20. Ionis Pharmaceuticals had a return on equity of 41.89% and a net margin of 45.64%. The firm had revenue of $192.00 million for the quarter, compared to analyst estimates of $159.59 million. During the same period last year, the company earned ($0.03) EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis.
In related news, SVP Patrick R. O’neil sold 4,400 shares of the business’s stock in a transaction that occurred on Thursday, January 3rd. The stock was sold at an average price of $54.80, for a total transaction of $241,120.00. Following the transaction, the senior vice president now directly owns 14,584 shares of the company’s stock, valued at approximately $799,203.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Richard S. Geary sold 999 shares of the business’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $60.00, for a total value of $59,940.00. Following the transaction, the senior vice president now directly owns 21,442 shares in the company, valued at $1,286,520. The disclosure for this sale can be found here. Insiders sold a total of 205,660 shares of company stock worth $12,739,354 over the last ninety days. Corporate insiders own 2.44% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Capital Investment Advisory Services LLC acquired a new position in Ionis Pharmaceuticals during the 4th quarter worth approximately $91,000. Hanseatic Management Services Inc. purchased a new stake in Ionis Pharmaceuticals during the 4th quarter worth approximately $440,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Ionis Pharmaceuticals by 82.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,709 shares of the company’s stock worth $957,000 after purchasing an additional 8,014 shares during the last quarter. Bank of Montreal Can increased its holdings in Ionis Pharmaceuticals by 95.2% during the 4th quarter. Bank of Montreal Can now owns 35,651 shares of the company’s stock worth $1,928,000 after purchasing an additional 17,386 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in Ionis Pharmaceuticals by 1.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 51,696 shares of the company’s stock worth $2,795,000 after purchasing an additional 554 shares during the last quarter. 84.84% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:IONS traded up $1.10 during mid-day trading on Friday, reaching $78.54. The company’s stock had a trading volume of 1,287,821 shares, compared to its average volume of 995,341. The company has a current ratio of 7.88, a quick ratio of 7.85 and a debt-to-equity ratio of 0.53. Ionis Pharmaceuticals has a twelve month low of $39.07 and a twelve month high of $78.59. The firm has a market cap of $10.60 billion, a price-to-earnings ratio of 26.53 and a beta of 2.40.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Read More: Certificate of Deposit (CD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.